东南大学学报(医学版)
東南大學學報(醫學版)
동남대학학보(의학판)
JOURNAL OF SOUTHEAST UNIVERSITY(MEDICAL SCIENCE EDITION)
2014年
5期
601-604
,共4页
伊班膦酸钠%辛伐他汀%2型糖尿病%骨质疏松
伊班膦痠鈉%辛伐他汀%2型糖尿病%骨質疏鬆
이반련산납%신벌타정%2형당뇨병%골질소송
sodium ibandronate%simvastatin%type 2 diabetes mellitus%osteoporosis
目的:探讨伊班膦酸钠联合辛伐他汀治疗对2型糖尿病( T2DM)合并骨质疏松症患者骨代谢指标( TRACP-5b、s-CTX、BAP、OC)及骨密度( BMD)的影响,为临床治疗T2DM合并骨质疏松症提供参考。方法:选择T2DM合并骨质疏松症患者115例,随机分为观察组(n=58)和对照组(n=57)。对照组给予常规治疗加用伊班膦酸钠注射液,观察组在对照组基础上联用辛伐他汀。观察两组治疗前、治疗12个月后血Ca、P、ALP、s-CTX、TRACP-5b、BAP、OC及BMD的变化。结果:观察组治疗12个月后TRACP-5b、s-CTX明显低于对照组(P<0.05),BAP、OC水平则明显高于对照组(P<0.05)。观察组治疗12个月后腰椎L2~4、股骨颈的BMD明显高于对照组( P<0.05)。结论:伊班膦酸钠联合辛伐他汀治疗T2 DM合并骨质疏松症可有效促进骨形成、抑制骨吸收、增加骨BMD,疗效明显优于单纯伊班膦酸钠。提示在防治T2DM合并骨质疏松症时,除了给予抑制骨吸收、促骨形成的药物治疗外,还应积极治疗T2DM,控制影响骨代谢的危险因素,如降血糖、改善胰岛素缺乏和脂代谢异常等,以进一步提高临床疗效。
目的:探討伊班膦痠鈉聯閤辛伐他汀治療對2型糖尿病( T2DM)閤併骨質疏鬆癥患者骨代謝指標( TRACP-5b、s-CTX、BAP、OC)及骨密度( BMD)的影響,為臨床治療T2DM閤併骨質疏鬆癥提供參攷。方法:選擇T2DM閤併骨質疏鬆癥患者115例,隨機分為觀察組(n=58)和對照組(n=57)。對照組給予常規治療加用伊班膦痠鈉註射液,觀察組在對照組基礎上聯用辛伐他汀。觀察兩組治療前、治療12箇月後血Ca、P、ALP、s-CTX、TRACP-5b、BAP、OC及BMD的變化。結果:觀察組治療12箇月後TRACP-5b、s-CTX明顯低于對照組(P<0.05),BAP、OC水平則明顯高于對照組(P<0.05)。觀察組治療12箇月後腰椎L2~4、股骨頸的BMD明顯高于對照組( P<0.05)。結論:伊班膦痠鈉聯閤辛伐他汀治療T2 DM閤併骨質疏鬆癥可有效促進骨形成、抑製骨吸收、增加骨BMD,療效明顯優于單純伊班膦痠鈉。提示在防治T2DM閤併骨質疏鬆癥時,除瞭給予抑製骨吸收、促骨形成的藥物治療外,還應積極治療T2DM,控製影響骨代謝的危險因素,如降血糖、改善胰島素缺乏和脂代謝異常等,以進一步提高臨床療效。
목적:탐토이반련산납연합신벌타정치료대2형당뇨병( T2DM)합병골질소송증환자골대사지표( TRACP-5b、s-CTX、BAP、OC)급골밀도( BMD)적영향,위림상치료T2DM합병골질소송증제공삼고。방법:선택T2DM합병골질소송증환자115례,수궤분위관찰조(n=58)화대조조(n=57)。대조조급여상규치료가용이반련산납주사액,관찰조재대조조기출상련용신벌타정。관찰량조치료전、치료12개월후혈Ca、P、ALP、s-CTX、TRACP-5b、BAP、OC급BMD적변화。결과:관찰조치료12개월후TRACP-5b、s-CTX명현저우대조조(P<0.05),BAP、OC수평칙명현고우대조조(P<0.05)。관찰조치료12개월후요추L2~4、고골경적BMD명현고우대조조( P<0.05)。결론:이반련산납연합신벌타정치료T2 DM합병골질소송증가유효촉진골형성、억제골흡수、증가골BMD,료효명현우우단순이반련산납。제시재방치T2DM합병골질소송증시,제료급여억제골흡수、촉골형성적약물치료외,환응적겁치료T2DM,공제영향골대사적위험인소,여강혈당、개선이도소결핍화지대사이상등,이진일보제고림상료효。
Objective: To investigate the bone metabolic markers ( TRACP-5b,s-CTX, BAP, OC) and bone mineral density (BMD) of patient with type 2 diabetes mellitus (T2DM) who was treated by ibandronate combined with simvastatin , in order to provide reference for clinical treatment of T 2 DM complicated with osteoporosis . Methods:One hundred and fifteen cases of patients with T 2 DM complicated with osteoporosis were randomly divided into observation group ( n=58 ) and control group ( n =57 ) .Patients in control group were given with ibandronate injection combined with conventional therapy , patients in observation group were treated with simvastatin on basis of treatment of patients in control group .The blood Ca, P, ALP, s-CTX, TRACP-5b,BAP, OC and BMD of patiets in two groups before treatment or at posttreatment 12 months were observed .Results:The TRACP-5b, s-CTX at posttreatment 12 months in observation group were significantly lower than those in control group (P<0.05), the BAP,OC levels were significantly higher than those in control group (P<0.05).The BMD of lumbar L2-4 , femoral neck in observation group at posttreatment 12 months were higher than that in control group(P<0.05).Conclusion:Treating T2DM complicated with osteoporosis by ibandronate combined with simvastatin can effectively promote bone formation , inhibit bone resorption ,increase BMD , its curative effect is obviously better than sodium ibandronate.Therefore, in prevention and treatment of T2DM complicated with osteoporosis, in addition to using drug about inhibiting bone resorption , promoting bone formation , actively treating T2DM, controlling effect of risk factors of bone metabolism such as lowering blood glucose , improving insulin deficiency and abnormal lipid metabolism should be done , so that clinical efficacy is further improved .